Du är här

2016-02-19

Biotie Therapies Oyj: Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE February 19,
2016 at 3.15 p.m.

Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act

Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the
"Company") has on February 19, 2016 received a notification in accordance
with Chapter 9, Section 5 of the Finnish Securities Markets Act, according to
which the holding of FMR LLC and its controlled entity FMR CO., Inc in
Biotie's shares and voting rights has fallen below the threshold of 5 per
cent on February 18, 2016.

Biotie's registered total number of shares and voting rights amounting to
1,089,608,083 has been used in the calculation of percentages for the
announcement.

Total positions of FMR LLC and its controlled entity FMR CO., Inc subject to
the notification:

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| % of shares and voting rights (total of A) % of shares and voting rights through financial instruments Total of both in % (A + B) |
| (total of B) |
| Resulting situation on the date on which threshold was crossed below 5 % below 5 % below 5 % |
|or reached |
| Position of previous notification (if applicable) 4.69 1.56 6.25 |
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Notified details of the resulting situation on the date on which the threshold
was crossed or reached:

A: Shares and voting rights

---------------------------------------------------------------------------------------------
| Class/type of shares Number of shares and voting rights % of shares and voting rights |
| |
|ISIN code (if possible) |
| Direct Indirect Direct Indirect |
| |
| (SMA 9:5) (SMA 9:6 and 9:7) (SMA 9:5) (SMA 9:6 and 9:7) |
| Shares - below 5 % - below 5 % |
| |
|(FI0009011571) |
| |
| SUBTOTAL A below 5 % below 5 % |
---------------------------------------------------------------------------------------------
B: Financial instruments according to SMA 9:6a

-------------------------------------------------------------------------------------------------------------------------------------------------------------------
| Type of financial instrument Expiration date Exercise/ Physical or cash settlement Number of shares and voting rights % of shares and voting rights |
| |
| Conversion period |
| Right of Recall N/A N/A Physical settlement below 5 % below 5 % |
| |
| SUBTOTAL B below 5 % below 5 % |
-------------------------------------------------------------------------------------------------------------------------------------------------------------------
Full chain of controlled undertakings through which the voting rights and/or
the financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity:

---------------------------------------------------------------------------------------------------------------------------------------------------
| Name % of shares and voting rights % of shares and voting rights through financial instruments Total of both |
| FMR LLC 0 0 0 |
| Fidelity Management&Research Company 0 0 0 |
| FMR CO., Inc below 5 % below 5 % below 5 % |
---------------------------------------------------------------------------------------------------------------------------------------------------
In Turku, February 19, 2016

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION:

Nasdaq Helsinki Ltd
Main Media
www.biotie.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biotie Therapies Oyj via Globenewswire

HUG#1987743

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.